Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome: Retrospective, Multicenter Study
Phase 3
18 Years
80 Years
18 Years
80 Years
Not Enrolling
Both
Myelodysplastic Syndromes
Both
Myelodysplastic Syndromes
Trial Information
Head to Head Comparison of Azacitidine and Decitabine in Myelodysplastic Syndrome: Retrospective, Multicenter Study
Among 300 MDS patient, 200 of them have been taking Azacitidine and 100 of them have been
taking Decitabine. Medical chart of these patients will be reviewed to assess the efficacy
and safety between two agents.
Inclusion Criteria:
- Confirmed MDS by bone marrow examination
- Receiving azacitidine and decitabine as a first line chemotherapy
- Adequate hepatic, cardiac, and renal function
Exclusion Criteria:
- Previously treated with another anti-cancer therapy due to MDS
- Not available for clinical information
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Response rate
Outcome Description:
Compare Azacitidine and Decitabine's treatment response rate in MDS patients
Outcome Time Frame:
6 months
Safety Issue:
No
Authority:
Korea: Institutional Review Board
Study ID:
H-1012-015-342
NCT ID:
NCT01409070
Start Date:
January 2011
Completion Date:
December 2011
Related Keywords:
- Myelodysplastic Syndromes
- MDS
- Myelodysplastic Syndromes
- Preleukemia
Name | Location |
|---|
